BlueHammer85
Well-Known Member
- Joined
- 13 Oct 2010
- Messages
- 37,055
England's R number has risen slightly to between 0.8 and 1.1,
Is this Regeneron/Roche?
According to the company, that treatment is effective in patients without their own immune response, but not in the wider population.
In those immune deficient patients, deaths reduced 20%, no effect in wider population.
REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2 | Regeneron Pharmaceuticals Inc.
TARRYTOWN, N.Y. , June 16, 2021 /PRNewswire/ -- UK RECOVERY investigators found REGEN-COV reduced risk of death by 20% in patients hospitalized with COVID-19 who had not mounted their own immune response (primary outcome for the primary analysis population) First trial to demonstrate that anyinvestor.regeneron.com
‘Life-saving’ Covid-19 monoclonal antibody treatment will be rolled out on the NHS next week
Ronapreve will be given to the most vulnerable patients in hospitals who are unable to build up an immune response to the virusinews.co.uk
Ronapreve a cocktail of The monoclonal antibody cocktail of casirivimab and imdevimab that was given to Trump.